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Venezuelan  (VEEV),  eastern,  and western  equine  encephalitis  viruses,  members  of the  genus Alphavirus,
are  causative  agents  of debilitative  and sometimes  fatal  encephalitis.  Although  human  cases  are  rare,
these  viruses  pose a threat  to  military  personnel,  and  to public  health,  due  to  their potential  use as
bioweapons.  Currently,  there  are  no  licensed  therapeutics  for  treating  alphavirus  infections.  To  address
this  need,  small-molecules  with  potential  anti-alphavirus  activity,  provided  by  collaborators,  are  tested
routinely  in  live  alphavirus  assays  utilizing  time-consuming  virus  yield-reduction  assays.  To expedite
the  screening/hit-confirmation  process,  a cell-based  enzyme-linked  immunosorbent  assay  (ELISA)  was
developed and  validated  for  the measurement  of VEEV  infection.  A signal-to-background  ratio  of  >900,
and  a z-factor  of  >0.8  indicated  the robustness  of this  assay.  For validation,  the  cell-based  ELISA was
compared  directly  to results  from  virus  yield  reduction  assays  in  a single  dose  screen  of 21  compounds.
Using  stringent  criteria  for anti-VEEV  activity  there  was  90%  agreement  between  the  two  assays  (com-
pounds  displaying  either  antiviral  activity,  or  no  effect,  in  both  assays).  A concurrent  compound-induced
cell  toxicity  assay  effectively  filtered  out  false-positive  hits. The  cell-based  ELISA  also  reproduced  suc-
cessfully  compound  dose–response  virus inhibition  data  observed  using  the  virus  yield  reduction  assay.
With  available  antibodies,  this  assay  can  be  adapted  readily  to  other  viruses  of  interest  to  the biodefense
community.  Additionally,  it is  cost-effective,  rapid, and  amenable  to  automation  and  scale-up.  There-
fore,  this  assay  could  expedite  greatly  screening  efforts  and  the  identification  of effective  anti-alphavirus
inhibitors.
Published by Elsevier B.V.
1. Introduction
The majority of viruses within the genus Alphavirus are non-
pathogenic to humans. However, select alphaviruses can cause
severe disease in humans and represent a significant threat to pub-
lic health. Venezuelan (VEEV), eastern (EEEV), and western equine
Abbreviations: BSA, bovine serum albumin; CHIKV, Chikungunya virus;
CPE, cytopathic effect; EEEV, eastern equine encephalitis virus; ELISA, enzyme-
linked immunosorbent assay; HRP, horseradish peroxidase; IC50, 50% inhibitory
concentration; MAb, monoclonal antibody; MOI, multiplicity of infection; PBS,
phosphate-buffered saline; pfu, plaque-forming units; RT, room temperature; S/B,
signal to background ratio; SD, standard deviation; TCID50, tissue culture infectious
dose 50; TrD, Trinidad donkey strain of VEEV; USAMRIID, United States Army Med-
ical Research Institute of Infectious Disease; VEEV, Venezuelan equine encephalitis
virus; WEEV, western equine encephalitis virus.
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encephalitis (WEEV) viruses, are causative agents of debilitative,
acute, and sometimes fatal encephalitis in North, Central, and South
America (Strauss and Strauss, 1994). Chikungunya virus (CHIKV),
an old world alphavirus, causes chikungunya fever, a febrile ill-
ness characterized by severe arthralgia (Schwartz and Albert, 2010;
Thiboutot et al., 2010). In 2005, a large outbreak of chikungunya
fever began in La Reunion, an island in the Indian Ocean. This out-
break caused over 300,000 cases and 237 deaths (Higgs, 2006), and
subsequently spread to India where over 1.5 million cases were
recorded. These alphaviruses are naturally maintained in a zoonotic
cycle between nonhuman vertebrate hosts and hematophagous
mosquito vectors. Natural human cases occur through the bite of an
infected mosquito. VEEV, EEEV, and WEEV are additionally recog-
nized as candidates for use as biological weapons, and are classified
as category B pathogens by the Centers for Disease Control and Pre-
vention and The National Institutes of Health (Reichert et al., 2009).
Given this threat, and the recent reemergence of CHIKV, there is a
critical need for an effective, broad-spectrum anti-alphavirus ther-
apeutic. Currently, there are no licensed drugs available for the
treatment of VEEV, EEEV, WEEV, or CHIKV infections.
0166-0934/$ – see front matter. Published by Elsevier B.V.
http://dx.doi.org/10.1016/j.jviromet.2013.06.007
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Alphavirus virions are small, spherical particles ∼70 nm in diam-
eter, with a nucleocapsid core surrounded by a host-derived lipid
membrane (Strauss and Strauss, 1994). The nucleocapsid is assem-
bled from 240 copies of viral capsid protein (C). Glycoprotein
spikes, composed of trimers of viral E1/E2 heterodimers are embed-
ded in, and extend from the viral membrane. To address the
need for alphavirus therapeutics, Prosetta Antiviral, Inc. developed
a cell-free, high-throughput screen to identify compounds that
interfere with alphavirus capsid assembly (manuscript in prepara-
tion). Preliminary hits from this screen, as well as small-molecules
from other collaborators, are routinely tested for anti-alphavirus
activity using standard, time-consuming, and labor-intensive virus
yield-reduction assays (standard plaque assay or tissue culture
infectious dose 50 [TCID50] assay). Although these traditional virus
titer assays can validate hits from preliminary screens, their use
represents a significant bottle-neck in the hit-confirmation pro-
cess.
The present study describes the development and validation
of a cell-based ELISA for the detection and quantitation of
VEEV infection in cell monolayers, and its suitability for use in
high-throughput screening applications. The ELISA reproduced
accurately data from a virus yield reduction assay in a single-
dose screen of 21 test compounds with potential anti-alphavirus
activity, and can also be used in the context of compound dose
curve analyses and IC50 (50% inhibitory concentration) calculations.
This assay is significantly less time-, labor-, and material-intensive
than virus yield reduction measurements using standard plaque
assay or TCID50 assay. A high signal-to-background ratio and high
z-factor value indicate that the cell-based ELISA method can be
adapted successfully for use in a high-throughput scenario. Based
on these data, the VEEV cell-based ELISA is suitable for, and will
expedite screening efforts to identify anti-VEEV small-molecule
inhibitors.
2. Materials and methods
2.1. Virus and cells
Virus infections were carried out with VEEV (subtype IA/B)
Trinidad donkey (TrD) strain obtained from USAMRIID archives.
Vero cells were obtained from USAMRIID Virology Department cell
culture core lab, and were maintained in Eagle’s Minimum Essential
Medium (EMEM) supplemented with non-essential amino acids,
and 10% fetal bovine serum (Life TechnologiesTM, Grand Island, NY).
Cells were incubated at 37 ◦C, in a humidified incubator, with 5%
CO2.
2.2. Cell-based ELISA
Confluent Vero cell monolayers in black 96-well plates (Greiner
Bio-one, Monroe, NC) were infected with VEEV TrD at various multi-
plicities of infection (MOIs). MOI  calculations utilized a cell number
(based on previous cell counts) of 4 × 104 Vero cells per confluent
well in a 96-well plate. Virus was diluted in complete medium and
was added to cells in 50 l volume. After 1 h virus was removed
and fresh medium added. At indicated time points after infection,
cells were fixed in 3.7% formaldehyde in phosphate-buffered saline
(PBS), at 4 ◦C for 18–24 h. Cells were washed in PBS and then blocked
with 3% bovine serum albumin (BSA, Sigma–Aldrich, St. Louis, MO)
in PBS for 1 h at room temperature (RT). Anti-VEEV E2 1A4A-1
monoclonal antibody (Roehrig and Mathews, 1985) (1 mg/ml) was
diluted in PBS + 3% BSA and added to cells for 2 h, RT. After washing
with PBS, cells were incubated with goat anti-mouse horseradish
peroxidase (HRP) secondary antibody (Invitrogen, Grand Island,
NY) diluted in PBS + 3% BSA for 1 h, RT. Cells expressing VEEV
E2 protein were detected with Super Signal ELISA Pico chemi-
luminescence substrate (Thermo Scientific, Waltham, MA)  (5 min
incubation, RT), and a Spectramax M5  plate reader (Molecular
Devices, Sunnyvale, CA).
For the compound screen using the ELISA, compounds were
diluted and mixed with VEEV virions for 4 h, 37 ◦C. The com-
pound/virus mixture was  then added to Vero cells plated in
black 96-well plates. Cells were incubated in the presence
virus/compound for 18 h. Cells were then fixed and processed
for ELISA as described above. Bafilomycin A1 (Enzo Life Sciences,
Farmingdale, NY) was  used as a positive control VEEV-inhibitory
compound in the ELISA (Hunt et al., 2011).
2.3. Cell viability
Compounds were diluted to the indicated concentrations in
complete media and added to Vero cells in black 96-well plates, in
100 l final volume. Cells were incubated for 48 h, at 37 ◦C, and then
moved to RT for 30 min. Cell Titer Blue reagent (20 l, Promega,
Madison, WI)  was added to cell culture supernatant in each well,
and incubated for 3 h at 37 ◦C. Fluorescence was then measured in
each well with a Spectramax M5  plate reader.
2.4. Virus yield reduction assay
Vero cells in 24-well plates were infected with VEEV TrD (MOI
10), for 1 h, 37 ◦C, in 100 l volume. After infection, the virus
inocula were removed, cells were washed twice with serum-free
medium. Complete medium (2% FBS + penicillin 0.5 mg/ml, strep-
tomycin 0.5 mg/ml) containing compound was  then added to the
cells (triplicate wells for each compound/concentration), and incu-
bated for 24 h, 37 ◦C. Cell culture supernatants from each well of
the 24-well plate were collected. Virus yield was determined by
TCID50 assay. Briefly, supernatants were diluted in 96-well plates
(five replicate dilution series for each well of the 24-well plate).
A 10-fold dilution series was generated from 10−1 to 10−8. The
serial dilutions were then transferred to Vero cells in 96-well
plates, and incubated for 6 d. Medium was removed and cells
were fixed and stained with 0.05% crystal violet in 3.7% formalde-
hyde for 30 min  at RT. Stain was removed and cells were rinsed
with water and air dried. Cytopathic effect (CPE) was observed
by visual inspection. The two  virus dilutions where CPE transi-
tioned from >50% (three or more replicate wells with CPE) to
<50% of replicates with CPE were recorded. TCID50 was deter-
mined by calculations described previously (Reed and Muench,
1938).
2.5. Statistics
For replicate 96-well plates containing cells infected with
VEEV (positive controls) or not infected (negative controls), t-
tests were used to compare plate 1 to plate 2 on each of two
days to assess plate-to-plate differences. For replicate 96-well
plates containing cells infected with VEEV or not infected, t-tests
were used to compare plates from day 1 to plates from day 2
to assess day-to-day differences. For 96-well plates containing
cells infected with VEEV in the presence of a cohort of 21 poten-
tial anti-VEEV compounds, the correlation coefficient (r) between
the virus yield reduction assay and the cell-based ELISA was
calculated, and used to determine if the correlation was statisti-
cally significant. Spearman’s rank correlation was  utilized. Using
the cell-based ELISA, and eight-point dose curve was analyzed
for compound 22. The IC50 value was  calculated using probit
analysis.
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3. Results
3.1. Optimization of a VEEV cell-based ELISA and characterization
of infection kinetics
In previous experiments, monoclonal antibody (MAb) 1A4A-1,
directed against VEEV E2 protein, has proven effective at detecting
viral antigen in immunofluorescence assays (Parker et al., 2010).
This antibody was evaluated for performance in a cell-based ELISA
format for the detection and quantitation of VEEV-infected Vero
cell monolayers in 96-well plates. MAb  1A4A and HRP-conjugated
secondary antibodies were titrated to determine optimal concen-
trations yielding maximized signal/background ratios (S/B). Vero
cells were infected with VEEV, at an MOI  of 0.01 plaque-forming
units per cell (pfu/cell), and incubated for 18 h. Cells were then fixed
and processed for cell-based ELISA. Four dilutions of MAb  1A4A
were tested with four dilutions of HRP-conjugated secondary anti-
body. After addition of the HRP substrate, luminescent signal was
recorded with a plate reader. A primary antibody dilution of 1:4000,
with a secondary antibody dilution of either 1:5000 or 1:10,000
yielded S/B ratios >900. All subsequent experiments were carried
out using a 1:4000 dilution of 1A4A, and HRP-conjugated secondary
antibody diluted 1:10,000.
Experiments were performed to determine the appropriate
virus dose (MOI) and infection time point to be used in small-
molecule screening efforts. Optimal parameters are necessary for
the detection of inhibition of infection (virus spread) in the pres-
ence of compounds with anti-VEEV activity. These parameters are
especially relevant when screening for inhibitors of viruses with
extremely fast replication cycles, such as VEEV (4 h) (Strauss and
Strauss, 1994). Vero cells were infected with VEEV at MOIs of 0,
0.0001, 0.001, 0.01, 0.1, and 1 pfu/cell. Infected cells were incubated
for 6, 18, or 24 h before fixation and processing for cell-based ELISA
(Fig. 1A). A low level of infection was detected at 6 h using MOIs
of 1 and 0.1. In contrast, the luminescent signal was near maxi-
mum  for most MOIs tested 24 h after infection. When measured
at 18 h after infection, the ELISA signal was virus dose-dependent,
and did not reach maximum levels (compared to 24 h data). High
variability was consistently seen at the very low MOI  of 0.0001, as
some replicate wells had infected cells and others no infection was
detected. Based on the 18 h virus dose–response curve, subsequent
small-molecule screening experiments were performed using MOI
0.01, infected for 18 h.
The suitability of the ELISA as an assay for high-throughput
screening was investigated next. Cells in two replicate 96-well
plates were infected with VEEV (MOI 0.01, 18 h), or not infected,
on two separate days (four plates total in analysis). Cells were fixed
and processed for ELISA (Fig. 1B). T-tests were utilized to assess
plate-to-plate and day-to-day variability. Briefly, t-tests compared
ELISA luminescence signal between plate 1 and 2 for each day
(experiment 1 and 2) for negative controls and positive controls
separately and combined. Likewise t-tests compared luminescence
signal between plates of experiments 1 and experiment 2. In each
case, the resulting p-values indicate that no statistically significant
differences were found (not shown). This analysis demonstrated
low plate-to-plate and day-to-day variability for the VEEV cell-
based ELISA. Using averaged data from all four plates, a z-factor
of 0.82 was calculated for this assay (Table 1).
3.2. Comparison of cell-based ELISA to virus yield reduction assay
in a limited screen for potential anti-VEEV small-molecule
inhibitors
A cohort of potential anti-VEEV compounds was supplied to
USAMRIID by Prosetta Antiviral, Inc. These compounds were subse-
quently tested for anti-VEEV activity using a virus yield reduction
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Fig. 1. Evaluation and optimization of a cell-based ELISA for the quantitation of
VEEV infection in 96-well plates. (A) A virus dose response and time course experi-
ment was performed to examine the kinetics of VEEV infection as measured by the
cell-based ELISA. Vero cells were infected at the indicated MOIs for 6, 18, or 24 h.
Luminescent ELISA signal is plotted for each MOI  and time point. (B) Determination
of  plate-to-plate and day-to-day variability of cell-based ELISA data. Duplicate plates
were infected with VEEV MOI  0.01 for 18 h, or not infected, and then processed for
ELISA. Two  independent experiments (Exp 1 and Exp 2) were carried out on sepa-
rate days. For each experiment, luminescence data for each well on duplicate plates
were averaged and plotted.
assay and the cell-based ELISA. For virus yield reduction assay, cells
were infected with VEEV (MOI 10) for 1 h. After incubation, excess
virus was removed, cells were washed with serum-free medium,
and complete medium containing compound (10 M),  or vehicle
control (dimethyl sulfoxide, DMSO, final concentration 0.1%) was
added. Infected cells were incubated with compound for 24 h. The
cell culture supernatant was  then collected and VEEV titer mea-
sured by TCID50 assay (Fig. 2A). Several compounds reduced VEEV
virus yield by >4 logs. Compounds with intermediate anti-VEEV
activity, or no activity, were also detected (Fig. 2A and Table 2).
Previous experiments demonstrated that DMSO does not influence
VEEV titer in this assay (not shown). This same cohort of com-
pounds was also tested for anti-VEEV activity using the cell-based
ELISA. A screening protocol was established that would detect
effectively compounds that act directly on virions, or that act on
intracellular protein targets. To this end, VEEV virions were mixed
Table 1
Z-factor determination for VEEV cell-based ELISA.
Wells n Meana SD Z′
Non-infected 96 2.65 0.14
0.82VEEV-infected 288 5.37 0.02
SD, standard deviation.
a Log10-transformed luminescence values.
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Fig. 2. Comparison of virus yield reduction assay and cell-based ELISA in a
small screen to identify anti-VEEV compounds. (A) Twenty-one small-molecule
compounds were screened for the ability to reduce VEEV yield. Titers in cell culture
supernatants were determined by TCID50 assay. Cells were infected with VEEV in
24-well plates for 1 h. After the infection period, medium was  added containing
compound (10 M),  or DMSO as a control (DM). VEEV titer (TCID50/ml) was mea-
sured in cell culture supernatants 24 h after the start of infection, and was  plotted
for each compound. (B) The same group of compounds was examined for anti-VEEV
activity using the cell-based ELISA. Virions were pre-treated with compound, or
not treated (NT) and subsequently used to infect cells. The compound + virus mix-
ture remained on cells through the 18 h incubation period. DMSO (DM) had no effect
Table 2
Results of small-molecule screen. Correlation between ELISA and virus yield reduc-
tion assay data.
Compound ELISA (% inhibition) TCID50 (decrease in titer)
1 >80% >4 log
2  <20% ∼1 log
3  >80% >2 log
4  >80% >4 log
5  >80% >4 log
6  <20% No decrease
7  >80% >4 log
8  >80% >4 log
9  >50% ∼3 log
10 >80% >4 log
11  <20% No decrease
12 >80% >4 log
13  <50% <2 log
14  >80% >4 log
15  >80% >4 log
16  >80% >2 log
17  >80% >4 log
18  >80% >4 log
19  <50% <2 log
20 >80% >4 log
21  >80% >4 log
with individual compounds and incubated at 37 ◦C for 4 h. The
virion/compound mixture (10 M compound final concentration)
was then added to Vero cell monolayers in a 96-well plate. This
infection mixture remained on the cells for 18 h. Cells were then
fixed and processed for ELISA. The data obtained with this assay
closely mirrored those of the virus yield reduction assay (Fig. 2B
and Table 2). Of the 21 compounds tested, 15 compounds reduced
ELISA signal by >80% of control (infected cells without compound
treatment). Each of these hits reduced virus yield by >2 logs, with
most (13/15) showing a >4 log reduction in virus titer. Spearman’s
rank correlation was utilized to evaluate the relationship between
TCID50 titers and ELISA luminescence for the cohort of potential
anti-VEEV compounds. The resulting correlation coefficient was
r = 0.88, and the corresponding p-value was  p < 0.0001, indicating
that there is evidence of a linear relationship between the virus
yield reduction and ELISA results (Fig. 2C). Overall, the cell-based
ELISA for quantitation of VEEV infection accurately recapitulated
virus yield reduction assay titer measurements made with TCID50
assay.
The observed compound-dependent reduction in ELISA signal,
or reduction in virus yield, could be the result of potent VEEV inhi-
bition, or the result of compound-induced cell toxicity. Compounds
producing significant toxicity could present as false-positives in
either of these assays. To help identify and filter out false positives,
at the time of infection for the ELISA, cells in a replicate plate were
exposed to compound without virus infection. Cells were incubated
for 48 h at 37 ◦C. Cell viability was  then measured using Cell Titer
Blue assay (Fig. 2D). Most compounds did not produce significant
toxicity, as measured by this particular assay. Compound 15 was
clearly toxic and reduced the viability-dependent fluorescent sig-
nal to 9% of the control wells. These data suggest that compound 15
is a false-positive hit in the ELISA and virus yield reduction assays,
and would be filtered out of further analysis. Two other compounds
on VEEV infection-dependent ELISA signal. Bafilomycin (Baf, 1 M) was used as a
positive control and effectively inhibited VEEV infection. Several compounds dra-
matically reduced ELISA signal after VEEV infection. (C) Average ELISA signal vs.
average TCID50 titer for each of 21 compounds. For each compound, ELISA lumines-
cence data and TCID50 titer data were log10 transformed and plotted on a scatter plot.
The linear regression line is shown. (D) Cell toxicity assay. Vero cells were treated
with each compound (10 M),  DMSO, or bafilomycin (1 M) for 48 h. Cell viability
was then measured using Cell Titer Blue assay. Viability-dependent fluorescent sig-
nal  was  recorded and plotted for each treatment. Most compounds had little effect
on  cell viability as measured by this assay.
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Fig. 3. Comparison of virus yield reduction assay and cell-based ELISA in a dose
response analysis of a non-toxic compound with anti-VEEV activity. (A) Compound
22  was  tested at three concentrations for the ability to decrease VEEV yield. A dose-
dependent inhibition of VEEV, compared to DMSO control (DM), was observed. (B)
An  8-point dose response for compound 22 was tested for VEEV inhibition with
the  cell-based ELISA. DMSO (DM) had little or no effect, while bafilomycin (Baf)
significantly inhibited VEEV. Treatment of cells with compound 22 resulted in a
dose-dependent inhibition of VEEV infection. (C) Cell Titer Blue viability assay after
48 h treatment with several doses of compound 22. No compound toxicity was
detected with this assay.
(10 and 17) produced a viability signal <80% of control cells, and
should be considered potential false-positives.
3.3. Dose-dependent anti-VEEV activity of compound 22
measured with virus yield reduction assay and ELISA
The VEEV-specific cell-based ELISA effectively detected small-
molecule compounds with anti-VEEV activity in a single dose
screen. These data also suggested that the ELISA could detect
compounds with intermediate or modest antiviral activity. The per-
formance of this assay was  examined in the context of a compound
dose–response experiment. Compound 22 demonstrated a dose-
dependent inhibition of VEEV production in Vero cells as measured
by the virus yield reduction assay (Fig. 3A). Treatment of cells with
200 nM compound 22 produced an ∼2 log reduction in VEEV titer
24 h after infection compared to DMSO-treated control cells. This
virus inhibition was lost at a compound concentration of 5 nM.
Using the cell-based ELISA and compound 22, an 8-point dose curve
analysis was performed (Fig. 3B). Starting with 500 nM,  a 2.5-fold
compound dilution series was generated and tested. Cells were
treated with compound and processed for ELISA as described for the
single-dose screen. Bafilomycin A1 was  used as a control and effec-
tively inhibited VEEV infection in this assay. The cell-based ELISA
method detected dose-dependent anti-VEEV activity of compound
22. Using DMSO as the positive control, an IC50 value of 50 nM was
calculated for this compound. The same compound dilutions were
added to cells, without virus infection, and incubated for 48 h. At
this time point no cellular toxicity was  detected with this assay at
any compound concentration tested (Fig. 3C).
4. Discussion
Screening assays to identify small-molecules with antiviral
activity can take several forms, each with their own  advantages
and disadvantages. On one end of the spectrum are in vitro cell-free
biochemical screens identifying inhibitors of a known and highly
purified protein target with a defined activity. Knowing the protein
target of identified inhibitors greatly facilitates downstream drug-
development efforts. However, the narrow focus of these assays,
searching for inhibitors of one specific protein, can also be described
as a disadvantage. Information regarding cell permeability or tox-
icity is also not readily available. Biochemical screens are typically
adapted easily to automation in 384- or 1536-well plate format,
achieving true high-throughput status, and do not require biosafety
level-3 (BSL-3) or BSL-4 high containment laboratories and the
restrictions that go along with working in that environment. This
study reports a cell-based screening strategy on the other end of the
spectrum, directly identifying inhibitors of authentic, pathogenic
VEEV.
In the cell-based ELISA screen described herein, the target of
any effective inhibitors is not known. However, this experimental
design allows investigators to cast a wide net, potentially iden-
tifying compounds that act directly on viral proteins, or on host
proteins. Additionally, compounds acting at any stage of the viral
lifecycle, from initial attachment to release of nascent viral particles
can be identified. In this assay, effective compounds, by definition,
have access to cellular and viral proteins. Cell toxicity data can
be obtained easily by running viability assays on duplicate plates,
but without virus infection. This strategy does require BSL3 con-
tainment. While it is possible to carry out initial large screens in
BSL1 or BLS2 laboratories using alternative viral reagents, such as
pseudotyped virus, attenuated viruses (i.e. VEEV vaccine strain TC-
83), or non-pathogenic viral replicon particles (VRPs), hits must
ultimately be tested against authentic virus. By screening directly
against wild-type pathogenic VEEV, the lead-hit generation process
is expedited greatly.
A possible disadvantage to a cell-based ELISA screening format
is the requirement of a suitable antibody detecting viral anti-
gen. These reagents are not readily available for some viruses.
The ELISA format is also more labor intensive than other possible
screening strategies for alphavirus inhibitors. For example, most
alphavirus infections produce a pronounced cytophathic effect
(CPE) in infected cells. This virus-induced loss of cell viability, or
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prevention of cell death by effective small-molecule inhibitors, can
be measured easily by common cell viability assays. Many of these
assays require the addition of only a single reagent to the cell cul-
ture, a short incubation time before reading the assay, and are
performed easily in 96- or 384-well plates. However, these assays
produced much lower signal-to-background ratios and z-factors
compared to the cell-based ELISA. The detection of a significant
loss of cell viability has also required either high MOIs or long
post-infection incubation times before reading the assay (72–96 h,
data not shown). Compounds showing significant but not complete
inhibition of VEEV infection were detected more easily with the
cell-based ELISA compared to several viability assays tested (not
shown).
A small number of screens utilizing diverse methodologies to
identify inhibitors of alphavirus infection have been reported. For
example, in vitro cell-free biochemical screens can be employed to
identify inhibitors of purified viral proteins (when protein activity
is known and amenable to assay development). This approach has
been applied to Semliki Forest virus (SFV) nsP1 protein (Lampio
et al., 1999). SFV nsP1 has methyltransferase activity, and is
involved in the capping of viral RNAs. Lampio et al. screened 58
cap analogs for the ability to inhibit nsP1 methytransferase activity.
Several inhibitors were identified with Ki values 40–400 M.  The
authors did not report cell toxicity testing or activity against live
virus in cell culture. Another cell-free approach, possible when viral
protein structural information is available, is in silico compound
screening. Using molecular modeling, compounds were designed
and synthesized that target the hydrophobic binding pocket of SINV
capsid protein (Kim et al., 2005). Select compounds inhibited virus
production effectively and were not toxic to uninfected BHK cells.
Cell-based assays reported in the literature include WEEV repli-
cons and SINV expressing luciferase as a marker protein (Peng et al.,
2009; Pohjala et al., 2008).
Although screens for anti-alphavirus inhibitors can take several
forms, identified compounds must be tested ultimately for activ-
ity against authentic, wild-type, pathogenic virus in cell culture
experiments. Although plaque assay remains a gold standard in the
eyes of many investigators, this technique is time-consuming, labor
intensive, and is not well suited for testing a large number of com-
pounds, and generating detailed dose response curves. The VEEV
cell-based ELISA described here does not rely on the use of non-
pathogenic alphaviruses, reporter systems, recombinant viruses,
or replicons. Additionally, the assay does not require overly expen-
sive or unwieldy equipment that is difficult to introduce, maintain,
and use in a high-containment laboratory setting. With available
antibodies, this assay can be adapted readily to other viruses of
interest to the biodefense community. Antibodies detecting EEEV
and WEEV glycoproteins for use in this ELISA assay format have
also been validated. Additionally, the assay is cost effective, rapid,
and amenable to automation and scale-up. Therefore, this assay
could expedite screening efforts and the identification of effective
anti-alphavirus inhibitors greatly.
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